Navigation Links
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Date:1/25/2012

tions of available therapies contribute to the significant unmet need of affected patients.  CMX001 has the potential to fill this major unmet need and become the standard of care with its broad spectrum coverage of multiple viral infections, favorable safety profile, and convenient oral dosing."

"We are extremely enthusiastic about the positive data emerging from Study 201 and our other clinical studies for CMX001," said Kenneth I. Moch, Chimerix President and Chief Executive Officer.  "We look forward to initiating Phase 3 studies during 2012."  

Additional CMX001 Presentations
Additional presentations at BMT Tandem will include data supporting use of CMX001 as peri-engraftment therapy for hematopoietic cell transplant recipients and in pediatric patients with adenovirus.  Poster presentations begin on Wednesday, February 1. 

  • "CMX001 in the Peri-Engraftment Period Does Not Impair Neutrophil Recovery in Pediatric Allogeneic Hematopoietic Stem Cell Recipients," will be presented by Michael S. Grimley, MD, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center.
  • "CMX001 as Therapy for Severe Adenovirus Infections in Immunocompromised Pediatric Patients: Single Experience in 5 Patients," which will also be presented by Dr. Grimley.

 

About CMX001
CMX001 is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate and has broad spectrum activity against dsDNA viruses. CMX001 is completing Phase 2 clinical development for the prophylaxis of cytomegalovirus (CMV) and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic cell transplant recipients. Efficacy results from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity seen in curr
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
2. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
3. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
4. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
5. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
6. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Chimerix to Present at the Citi 2011 Global Health Care Conference
9. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 10 Eli Lilly and Company (NYSE: LLY ... the Second Circuit has agreed with Lilly,s position that a ... payor suit, in which unions and insurers who act as ... court also agreed with Lilly that plaintiffs, overpricing claims should ...
... (NYSE Amex: PTN ) announced that it will ... Conference / 12th Annual Healthcare Conference on Tuesday, September 14, ... September 12-15 at the New York Palace Hotel in New ... Chief Executive Officer of Palatin Technologies, will provide an update ...
Cached Medicine Technology:U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... effects, is serious enough to be considered a health risk. ... or fewer hours were more likelier to have a heart ... too much sleep isn't good, either, as researchers found that ... also increased their heart disease risk. ,The study, conducted ...
... rate for potential medical problems, according to earlier studies, is ... for babies in hospitals are even higher. However, a new ... Agency for Healthcare Research and Quality (AHRQ) may help prevent ... is aimed at pediatricians and parents, and includes a fact ...
... the United States have found that the practice of ... past 14 years. However, they suggested that patients with ... Pylori(H.Pylori) infection rather than receiving treatment for the infection ... appropriate option// than empiric treatment in patients with peptic ...
... wasting condition which is a serious problem in people with ... bowel, liver, lungs and heart. A recent study has found ... in fruit flies, where it is involved in muscle development, ... ,Researchers have been studying the function of the twist ...
... has identified independent factors that are associated with ... the study, information was gathered from the 1999 ... evaluate common factors in 1,810 diabetic Americans.// ... were found to have more primary care and ...
... The myth that eating nuts makes one fat has ... mono and polyunsaturated fats are good while simple carbohydrates ... low-density lipoprotein cholesterol, the good kind. Monounsaturated fat does ... in heart disease. ,Preliminary evidence shows that even ...
Cached Medicine News:
Designed to meet the demands of today's laboratories for RO water....
... L/day of Type III Laboratory-grade Water, RiOs ... up to 8000 L/day of Type III ... Complete Purification and Control Unit, RiOs systems ... providing total control of all parameters within ...
... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
... Model U410 is an upright freezer ... our Innova line, but using conventional ... a cost-effective alternative. Similar in size ... 240 2" boxes. Includes five compartments ...
Medicine Products: